OncoLab Co. Ltd.
- Biotech or pharma, therapeutic R&D
- Biotech or pharma, animal health
OncoLab Co., Ltd. is developing ANGel platform (Antibody-conjugated nanogel) for subcutaneous, sustained delivery of cancer immunotherapeutics.
ANGel enables precise and durable delivery of antibodies, peptides, small molecules, as well as existing ADCs and bispecific antibodies, targeting tumors and immune cells.
In triple-negative breast cancer (TNBC), our lead program achieved ~50% complete remission in preclinical models.
We are now advancing toward clinical translation and global co-development partnerships.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}